# Olanzapine

## Okpine F.C. 5mg

| TAH Drug Code      | [OOKP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OOKP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Schizophrenia and other mental illnesses with obvious positive and/or negative characteristics, manic episodes of bipolar disorders, and prevention of recurrence of bipolar disorders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Dosing             | Adults: Initial dose: Schizophrenia: 10mg QD; manic episodes of bipolar disorder: monotherapy 15mg QD, combined therapy 10mg QD; prevent the recurrence of bipolar disorder:10mg QD. The daily dose can be adjusted to 5-20 mg/day according to the patient's clinical condition. The dosing interval should not be less than 24 hours. The elderly, >65 years old: consider using a lower initial dose (5 mg/day) Children: Lack of safety and efficacy data. Not recommended for people under 18 years of age.                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to olanzapine or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | >10%: Cardiovascular: Orthostatic hypotension (3-20%) Central nervous system: Drowsiness(20-39%), extrapyramidal reaction (10-32%), akathisia (3-27%), parkinsonian-like syndrome (14% to 20%), dizziness (8-11%), headache (adolescents 17%), fatigue (2% to 14%), insomnia (12%) Endocrine & metabolic: Increased serum prolactin (30-47%), weight gain (5-40%) Gastrointestinal: Increased appetite (3-29%), xerostomia (3-22%), dyspepsia (3-11%), constipation (4-11%) Hepatic: Increased serum AST (adolescents 28%), decreased serum bilirubin (adolescents 22%), increased serum ALT (?3 x ULN; adolescents and adults 5% to 12%) Neuromuscular & skeletal: Weakness (8-20%) Miscellaneous: Accidental injury (12%) |
| Pregnancy          | Compatible â€“ Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/olanzapine-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

